RESISTANCEPLUS
LIVE

Serial Number

79182819

Owner

SpeeDx Pty Ltd

Attorney

Mainak H. Mehta

Filing Date

Nov 30, 2015

Add to watchlist:

No watchlists yet
View on USPTO

RESISTANCEPLUS Trademark

Serial Number: 79182819 • Registration: 5220218

RESISTANCEPLUS is a trademark filed by SpeeDx Pty Ltd on November 30, 2015. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

SpeeDx Pty Ltd (21 trademarks)

Suite G16, National Innovation Centre,

Entity Type: 82

Trademark Details

Filing Date

November 30, 2015

Registration Date

June 13, 2017

Published for Opposition

March 28, 2017

Goods & Services

Chemicals used in industry, science, photography; chemicals used in agriculture, horticulture and forestry except fungicides, herbicides, insecticides, and parasiticides; chemical reagents and reactants in this class for non-medical purposes; enzymes for industrial purposes, namely, for use in the biotechnology industry; nucleic acid sequences, other than medical and veterinary purposes; nucleic recombinant acids; acids, namely, inorganic acids; organic acids for use in the biotechnology industry; DNA polymerase, other than medical and veterinary purposes; chemicals used in food processing and screening; chemicals used in environmental monitoring

Surgical, medical and veterinary apparatus and instruments, namely, surgical apparatus and instruments for medical or veterinary use; diagnostic testing apparatus and instruments for medical purposes, namely, for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; point of care medical devices for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; medical screening apparatus in this class for the detection of diseases, detection and identification of pathogens, detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression and immune disorders, for genotyping, for analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy

Pharmaceutical and veterinary preparations and substances for the diagnosis of diseases or detection or identification of pathogens for medical and veterinary purposes; reagents for medical and veterinary use; nucleic acid amplification reagents for medical use; nucleic acid sequencing programs for medical use; chemical preparations containing enzymes for medical purposes for the diagnosis of diseases or detection or identification of pathogens; chemical preparations containing enzymes for pharmaceutical, veterinary and medical purposes for the diagnosis of diseases or detection or identification of pathogens; enzymes for pharmaceutical, veterinary and medical purposes; medical kits in this class consisting of catalytic DNA molecules and associated detection reagents for the diagnosis of diseases, for detection and identification of pathogens, for the detection of antibiotic resistance, for the analysis of gene expression, protein expression, metabolite expression, inflammation, and immune-suppression and immune disorders, for genotyping, analysis of polymorphisms, detection of acquired or inherited genetic mutations, detection and analysis of epigenetic alterations, and for analysis of response to therapy; diagnostic reagents for medical or veterinary use; biological chemical test kits for medical laboratory use in analysis of gene expression, protein expression, metabolite expression, inflammation, immune-suppression, immune disorders

Filing History

INTERNATIONAL REGISTRATION RENEWED
Oct 16, 2025 RNWL
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Feb 22, 2024 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Feb 21, 2024 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 12, 2024 APRE
TEAS SECTION 71 & 15 RECEIVED
Jun 6, 2023 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 13, 2022 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 28, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 20, 2017 FICS
FINAL DISPOSITION PROCESSED
Sep 20, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 13, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 13, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 28, 2017 NPUB
PUBLISHED FOR OPPOSITION
Mar 28, 2017 PUBO
NEW REPRESENTATIVE AT IB RECEIVED
Mar 10, 2017 NREP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 8, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 22, 2017 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 13, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 13, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 13, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 13, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 13, 2017 CNEA
NEW REPRESENTATIVE AT IB RECEIVED
Feb 10, 2017 NREP
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 7, 2017 GNFN
FINAL REFUSAL E-MAILED
Feb 7, 2017 GNFR
FINAL REFUSAL WRITTEN
Feb 7, 2017 CNFR
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 1, 2017 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 1, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 1, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 1, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 1, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 1, 2017 CNEA
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Jan 23, 2017 LIME
NEW REPRESENTATIVE AT IB RECEIVED
Dec 16, 2016 NREP
LIMITATION OF GOODS RECEIVED FROM IB
Dec 8, 2016 LIMG
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 16, 2016 GNFN
FINAL REFUSAL E-MAILED
Sep 16, 2016 GNFR
FINAL REFUSAL WRITTEN
Sep 16, 2016 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 15, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 15, 2016 CRFA
ASSIGNED TO LIE
Sep 10, 2016 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 2, 2016 TROA
REFUSAL PROCESSED BY IB
Mar 19, 2016 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 2, 2016 RFCS
REFUSAL PROCESSED BY MPU
Mar 2, 2016 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 2, 2016 RFCR
NON-FINAL ACTION WRITTEN
Mar 1, 2016 CNRT
ASSIGNED TO EXAMINER
Feb 29, 2016 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 27, 2016 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 22, 2016 REPR